Aurobindo receives FDA approval for Fondaparinux Sodium Injection!
On December 27, 2017 Aurobindo received FDA approval for Fondaparinux Sodium Injection which is used to prevent deep vein thrombosis (DVT). This approved product has an estimated market size of $73 million for the twelve months ending October 2017 according to IMS. PR USFDA FA – Fondaparinux Sodium Injection[...] Read more
Aurobindo Pharma USA receives The 2017 Community Enhancement Award presented by East Windsor Township!
It is an East Windsor Township tradition to recognize businesses – how important they are to the community, how proud the township is of them and how they contribute to the community – every year, Mayor Janice Mironov said. There are three awards – the Business Beautification Award, the Community Service Award and the Community[...] Read more
Making our way into the Oncology space
AuroMedics has big plans in the coming years. Breaking into the oncology space is one piece of that puzzle. Follow the link below for additional information Aurobindo aims at cancer as it climbs the value chain[...] Read more
AuroMedics makes a statement at ASHP Mid-Year 2017
December 03 through 06 of 2017 marked the 75th year of the annual ASHP Midyear Clinical Meeting. With attendance rising to 25,000, this is the largest gathering of pharmacy professionals in the world. AuroMedics was proud to have our largest presence with a custom 20×30 foot booth, which helped showcase some of our most in demand products[...] Read more
Aurobindo Receieves FDA approval for Zoledronic Acid 5 mg/100 mL Single-Dose Vials!
On December 08, 2017 Aurobindo received FDA approval for Zoledronic Acid which is a bisphosphonate indicated for treatment of Paget’s disease of bone in men and women. Zoledronic Acid has an estimated annual market of $17.5 million according to IMS data running through October 2017.[...] Read more